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Low Herpesvirus Entry Mediator (HVEM) Expression
on Dermal Fibroblasts Contributes to a Th2-Dominant
Microenvironment in Advanced Cutaneous
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Yoshihide Asano1, Yayoi Tada1, Takafumi Kadono1 and Shinichi Sato1
LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein
D for herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes) is a ligand for HVEM.
LIGHT–HVEM interactions are important in T helper type 1 (Th1) immune responses. In some cases with early
stages of cutaneous T cell lymphoma (CTCL), IL-2, IFN-g, and Th1 chemokines are expressed in lesional skin,
while IL-4, IL-5, and Th2 chemokines are dominant in advanced CTCL. In this study, we investigated roles of
LIGHT and HVEM in the microenvironment of CTCL. LIGHT enhanced production of Th1 chemokines, such as
CXC chemokine ligand (CXCL) 9, CXCL10, and CXCL11, from IFN-g-treated dermal fibroblasts via phosphoryla-
tion of inhibitor kBa. Messenger RNA levels of these chemokines were increased in lesional skin of early CTCL.
Interestingly, while LIGHT expression in CTCL skin correlated with disease progression, HVEM expression was
significantly decreased in advanced CTCL skin. HVEM was detected in dermal fibroblasts in early CTCL skin, but
not in advanced CTCL skin in situ. These results suggest that low HVEM expression on dermal fibroblasts in
advanced CTCL skin attenuates expression of Th1 chemokines, which may contribute to a shift to a Th2-
dominant microenvironment as disease progresses.
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INTRODUCTION
LIGHT (lymphotoxin-like, exhibits inducible expression, and
competes with herpes simplex virus glycoprotein D for
herpesvirus entry mediator (HVEM), a receptor expressed by
T lymphocytes) is also known as tumor necrosis factor (TNF)
superfamily 14. LIGHT is expressed on activated T cells and
immature dendritic cells (Morel et al., 2000, 2001). LIGHT
binds to three distinct receptors: HVEM, lymphotoxin b
receptor (LTbR), and decoy receptor 3 (Mauri et al., 1998;
Zhai et al., 1998; Yu et al., 1999). Among them, HVEM is
expressed by many cell types, including T cells, B cells,
natural killer cells, dendritic cells, and fibroblasts (Harrop
et al., 1998; Granger and Ware, 2001; Morel et al., 2001;
Duhen et al., 2004; Pierer et al., 2007; Hosokawa et al.,
2010). LTbR, by contrast, is expressed predominantly on
stromal and epithelial cells (Endres et al., 1998; Murphy
et al., 1998; Browning and French, 2002). Decoy receptor 3
acts as a soluble inhibitory factor by binding LIGHT (Shi
et al., 2002).
LIGHT, expressed on T cells or dendritic cells, co-
stimulates and enhances T cell development (Mauri et al.,
1998). It also enhances production of cytokines, including
T helper type 1 (Th1) cytokines, such as IFN-g and IL-12, by
T cells and natural killer cells (Tamada et al., 2000; Fan et al.,
2006; Xu et al., 2007). The enhancement in T or natural killer
cell activation is a result of HVEM-mediated signaling, as
LTbR is not expressed on mature T cells (Force et al., 1995).
LIGHT also induces Th1 chemokine secretion from IFN-g-
stimulated human gingival fibroblasts (Hosokawa et al.,
2010). On the basis of these reports, LIGHT–HVEM interac-
tions likely promote Th1 immune responses.
Mycosis fungoides and Se´zary syndrome (SS) are the most
common types of cutaneous T cell lymphoma (CTCL)
(Willemze et al., 2005). Mycosis fungoides is characterized
by proliferation of neoplastic CD4þ T cells that preferentially
traffic to the skin. Patients with mycosis fungoides have a
classically prolonged clinical course and only limited cases
progress over years through patch, plaque, and tumor
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stages. SS is characterized by fever, erythroderma, lym-
phadenopathy, and leukemic involvement, and usually
has a rapid clinical course. CTCL is regarded as a Th2
disease, with eosinophilia and high levels of immunoglobulin
E and CC chemokine ligand (CCL) 17 often detected in
patients in advanced stages (Kakinuma et al., 2003; Sugaya,
2010). We also reported high levels of Th2 chemokines,
CCL11 and CCL26, in patients with CTCL (Miyagaki et al.,
2010). Early data have also suggested that tumor cells of SS
have Th2-like properties with increased IL-4 and IL-5 (Vowels
et al., 1992; Dummer et al., 1998). In early stages of
disease, however, polarized Th2 cytokine patterns were not
detectable among cultured skin-infiltrating T cells (Harwix
et al., 2000). In some cases, lesional T cell infiltrates and
peripheral blood T cells exhibit a Th1 cytokine pattern,
evidenced by increased expression of IL-2 and IFN-g (Vowels
et al., 1994; Asadullah et al., 1996a, 1996b; Papadavid et al.,
2003). Th1 chemokines, such as CXC chemokine ligand
(CXCL) 9 and CXCL10, are also reported to be expressed in
lesional skin of early CTCL, when epidermotropism of tumor
cells is remarkable (Tensen et al., 1998). It is unknown what
contributes to a shift to a Th2 microenvironment as CTCL
progresses. A Th2-dominant environment promotes tumor
survival and progression, as IFN-g-producing Th1 cells augment
antitumor immune responses. Indeed, IFN-g has proved to be
an effective therapy for CTCL (Kaplan et al., 1990).
In this study, we investigated LIGHT and HVEM interac-
tions in the setting of CTCL. Our findings suggest that low
HVEM expression on dermal fibroblasts in advanced CTCL
skin attenuates expression of Th1 chemokines, which may
contribute to a shift to a Th2 microenvironment as disease
progresses.
RESULTS
LIGHT augments CXCL9, CXCL10, and CXCL11 mRNA and
protein expression by IFN-c-treated dermal fibroblasts
We first examined HVEM expression on normal human
dermal fibroblasts. HVEM was only expressed at low
levels on the surface and its expression was significantly
enhanced by IFN-g (Figure 1a and b). IL-4 did not influence
HVEM expression levels. As LIGHT augments CXCL10 and
CXCL11 expression by IFN-g-treated gingival fibroblasts
(Hosokawa et al., 2010), we next treated dermal fibroblasts
with LIGHT, IFN-g, or their combination. As expected,
under serum-free conditions, CXCL9, CXCL10, and CXCL11
mRNA expression was increased in IFN-g-treated dermal
fibroblasts (Figure 1c). LIGHT augmented CXCL9, CXCL10,
and CXCL11 mRNA expression by IFN-g-treated dermal
fibroblasts in a dose-dependent manner, whereas LIGHT
alone did not increase the expression of these chemokines.
We also found that supernatant levels of CXCL9, CXCL10,
and CXCL11 were increased by stimulation with IFN-g, and
LIGHT enhanced chemokine production further in a dose-
dependent manner (Figure 1d). LIGHT alone did not increase
the chemokine levels. Thus, LIGHT treatment augmented
CXCL9, CXCL10, and CXCL11 production in IFN-g-stimu-
lated human dermal fibroblasts at both mRNA and
protein levels.
LIGHT enhances CXCL9, CXCL10, and CXCL11 expression by
IFN-c-treated dermal fibroblasts via phosphorylation of IjBa
We next examined whether LIGHT would induce phosphor-
ylation of inhibitor kBa (IkBa) in dermal fibroblasts, as was
previously reported in other cell types (Marsters et al., 1997;
Kim et al., 2005; Hosokawa et al., 2010). Phosphorylation of
IkBa triggers activation and enhanced transcriptional activity
of NF-kB. We first confirmed the presence of IkBa and no
phosphorylation of IkBa in untreated or IFN-g-treated dermal
fibroblasts (Figure 2a). LIGHT, in the presence or absence of
IFN-g, markedly increased phosphorylated IkBa (pIkBa) and
degradation of IkBa. We next used sc-514, an inhibitor of IkB
kinase 2. CXCL9, CXCL10, and CXCL11 mRNA and protein
expression levels by dermal fibroblasts co-stimulated with
LIGHT and IFN-g were significantly blocked by sc-514
(Figure 2b and c). On the other hand, sc-514 did not suppress
CXCL9, CXCL10, and CXCL11 expression by IFN-g-treated
dermal fibroblasts in the absence of LIGHT. Thus, activation
of NF-kB is necessary for LIGHT-mediated enhancement of
CXCL9, CXCL10, and CXCL11 expression by IFN-g-treated
dermal fibroblasts.
Increased LIGHT mRNA expression and decreased HVEM
mRNA expression in lesional skin of advanced CTCL
To investigate the role of LIGHT in the progression of CTCL,
we examined CXCL9, CXCL10, and CXCL11 mRNA expres-
sion in early and advanced CTCL skin. As expected, mRNA
expression of these chemokines was significantly elevated in
early CTCL skin compared with normal skin (Po0.01, 0.01,
and 0.05, respectively) or advanced CTCL skin (Po0.01,
0.05, and 0.05, respectively; Figure 3a). In advanced CTCL
skin, CXCL9, CXCL10, and CXCL11 mRNA expression levels
were significantly decreased relative to those in early CTCL
skin and were not higher than that in normal skin. We next
measured mRNA expression levels of CXC chemokine
receptor (CXCR) 3, a receptor for CXCL9, CXCL10, and
CXCL11, and CC chemokine receptor (CCR) 4, which is
expressed on tumor cells of advanced CTCL (Ferenczi et al.,
2002; Sokolowska-Wojdylo et al., 2005). CXCR3 mRNA
expression was significantly elevated in lesional skin of early
and advanced CTCL compared with normal skin (Po0.05
and 0.05, respectively; Figure 3b), whereas CCR4 mRNA
expression was significantly elevated only in advanced CTCL
compared with normal skin (Po0.05; Figure 3b). These
results are consistent with previous reports (Kakinuma et al.,
2003; Yagi et al., 2006).
We next investigated LIGHT and HVEM mRNA expression
in CTCL skin. Interestingly, HVEM mRNA expression in
advanced CTCL skin was significantly lower than that in
normal skin or early CTCL skin (Po0.05 and o0.05,
respectively; Figure 3c). LIGHT mRNA expression in ad-
vanced CTCL skin was significantly higher than that in
normal skin, but was comparable to that in early CTCL skin
(Po0.05). Moreover, cultured dermal fibroblasts from le-
sional skin of advanced CTCL expressed significantly lower
amounts of HVEM mRNA compared with those from normal
skin (Po0.05; Figure 3d). LTbR mRNA expression in dermal
fibroblasts from advanced CTCL was unchanged (data not
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shown). Thus, mRNA expression of CXCL9, CXCL10, CXCL11,
and their receptor CXCR3 was significantly upregulated in
early CTCL, whereas CXCR3, CCR4, and LIGHT mRNA
expression levels were significantly increased in advanced
CTCL. HVEM mRNA expression in lesional skin and dermal
fibroblasts from advanced CTCL was significantly down-
regulated, which may explain the decrease in CXCL9,
CXCL10, and CXCL11 expression.
Correlations among chemokines, chemokine receptors, LIGHT,
and HVEM mRNA expression levels in lesional skin of CTCL
We next examined whether mRNA expression levels of
chemokines, chemokine receptors, LIGHT, and HVEM in
lesional skin of CTCL were correlated with one another.
CXCL9 and CXCL10 mRNA expression levels significantly
correlated with HVEM mRNA expression levels (r¼0.58,
Po0.01, r¼ 0.46, Po0.05, respectively; Figure 4a), while
they did not correlate with LIGHT mRNA expression levels
(data not shown). CCR4 mRNA expression significantly
correlated with LIGHT mRNA expression (r¼0.68,
Po0.01) and inversely correlated with HVEM mRNA
expression (r¼0.38, Po0.05; Figure 4b). Moreover, LIGHT
mRNA expression in lesional skin of CTCL significantly
inversely correlated with HVEM mRNA expression
(r¼0.60, Po0.01; Figure 4c). CXCL9, CXCL10, and
CXCL11 mRNA expression levels correlated with one another
(Figure 4d). Thus, high expression of HVEM mRNA in lesional
skin is associated with early CTCL, whereas that of LIGHT is
associated with advanced CTCL.
Expression of HVEM, LIGHT, CXCL9, CXCL10, CXCL11, and
pIjBa in lesional skin of CTCL in situ
We immunolabeled paraffin-embedded skin samples of early
and advanced CTCL (n¼ 15) and normal skin (n¼5) for
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Figure 1. CXC chemokine ligand (CXCL)9, CXCL10, and CXCL11 expression by dermal fibroblasts co-stimulated with LIGHT (lymphotoxin-like, exhibits
inducible expression, and competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed by
T lymphocytes) and IFN-c. (a, b) Normal human dermal fibroblasts were cultured with medium only or with IFN-g or IL-4 (1, 10, and 100ngml1) for
24 hours. (a) HVEM expression on fibroblasts shown by flow cytometry. (b) Summary of HVEM expression on cultured fibroblasts. (c, d) Dermal fibroblasts
were cultured with medium only or with IFN-g (10 ngml1) or with LIGHT (1, 10, and 100ngml1) or with their combination for 24 hours. (c) Quantitative
reverse transcriptase (RT)–PCR was performed to measure CXCL9, CXCL10, and CXCL11 expression relative to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). (d) CXCL9, CXCL10, and CXCL11 levels in the culture supernatants were measured. Data are presented as mean±standard deviation.
*Po0.05. Results are representative of three experiments with similar findings.
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CXCL9, CXCL10, CXCL11, HVEM, LIGHT, and pIkBa. The
numbers of fibroblasts expressing CXCL9, CXCL10, and
CXCL11 in early CTCL skin were significantly higher than
that in normal skin (Figure 5a and b; Po0.01). These
chemokines were expressed only in some cases of advanced
CTCL, and the numbers of fibroblasts expressing CXCL9 and
CXCL 10 in advanced CTCL skin were significantly lower
than that in early CTCL skin (Po0.05). The numbers of
fibroblasts expressing HVEM in early CTCL skin were
significantly higher than that in normal skin (Figure 5a and
c; Po0.01). HVEM expression on dermal fibroblasts in CTCL
lesional skin was decreased as disease progressed, and the
numbers of fibroblasts expressing HVEM in advanced CTCL
skin were significantly lower than that in early CTCL skin
(Po0.05). Interestingly, HVEM expression on fibroblasts in
lesional skin of atopic dermatitis was similar to advanced
CTCL skin, whereas expression in psoriatic skin was similar to
early CTCL skin (Figure 5c and data not shown). LIGHT was
expressed in skin-infiltrating lymphocytes in each section. In
CTCL, the number of LIGHT-positive lymphocytes increased
as disease progressed (Figure 5a). The numbers of fibroblasts
expressing pIkBa in early CTCL skin were significantly higher
than that in normal skin (Figure 5a and d; Po0.01). The
expression of pIkBa in dermal fibroblasts in advanced CTCL
skin was similar to that in early CTCL. Thus, HVEM, CXCL9,
CXCL10, CXCL11, and pIkBa were highly expressed in dermal
fibroblasts in early CTCL skin. In contrast, expression of
HVEM, CXCL9, and CXCL10 was low in advanced CTCL skin.
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Figure 2. CXC chemokine ligand (CXCL)9, CXCL10, and CXCL11 expression induced by LIGHT (lymphotoxin-like, exhibits inducible expression, and
competes with herpes simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes) via phosphorylation
of inhibitor jBa (IjBa). (a) Human dermal fibroblasts were cultured with IFN-g (10 ngml1) or LIGHT (100 ngml1) or their combination. IkBa
phosphorylation was detected in fibroblasts stimulated with LIGHT, but not with IFN-g alone. A representative picture of three experiments is shown.
(b, c) Human dermal fibroblasts were cultured with medium only or with IFN-g (10 ngml1) or LIGHT (1, 10, and 100ng/ml1) or their combination for
16 hours after pre-incubation with medium or sc-514 (20 and 50 mM). (b) Quantitative reverse transcriptase (RT)–PCR was performed to measure CXCL9,
CXCL10, and CXCL11 expression relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (c) CXCL9, CXCL10, and CXCL11 levels in the culture
supernatants were measured. Data are presented as mean±standard deviation. *Po0.05. Results are representative of three experiments.
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HVEM expression on circulating tumor cells in SS
We next examined HVEM expression on T cells. We
collected peripheral blood mononuclear cells from three
patients with SS and analyzed HVEM expression by flow
cytometry. Interestingly, malignant T cell clones expressed
low levels of HVEM compared with benign T cells (Figure
5e). Frequencies of HVEM-positive cells were significantly
lower in malignant clonal T cells when compared with
benign T cells (Figure 5f). Thus, tumor cells in peripheral
blood of SS express low levels of HVEM.
DISCUSSION
In this study, we showed that dermal fibroblasts, when co-
stimulated with LIGHT and IFN-g, expressed abundant
CXCL9, CXCL10, and CXCL11, all of which are ligands for
CXCR3 (Figure 1). LIGHT alone did not induce expression of
these chemokines, as was reported with gingival fibroblasts
(Hosokawa et al., 2010). We also found that LIGHT
stimulation induced phosphorylation of IkBa, leading to
NF-kB activation (Figure 2a), which was also consistent with
previous reports (Marsters et al., 1997; Kim et al., 2005).
We did not detect phosphorylation of IkBa when dermal
fibroblasts were stimulated with IFN-g alone (Figure 2a).
Moreover, sc-514, an inhibitor of IkB kinase 2, did not
suppress CXCL9, CXCL10, and CXCL11 expression by IFN-g-
treated dermal fibroblasts (Figure 2b and c), suggesting that
NF-kB activation is not required for CXCL9, CXCL10, and
CXCL11 production by IFN-g-treated dermal fibroblasts. On
the other hand, tumor necrosis factor-a, IL-18, and prolactin,
which all enhance production of CXCR3 ligands by IFN-g,
induce phosphorylation of IkBa (Hardaker et al., 2004;
Kanda and Watanabe, 2007; Kanda et al., 2007). As
fibroblasts stimulated by LIGHT alone do not induce the
expression of CXCR3 ligands, IkBa phosphorylation may be
0.5 1.5
1.2
0.9
0.6
0.3
0
0.4
0.3
0.2
0.1
0
0.2
0.15
0.1
0.05
0
0.2
0.3
0.1
0
0.12
0.16
0.08
0.2
0.04
0 0
10–4
10–3
10–2
10–1
0.4
0.3
0.2
0.1
0
0.012
0.01
0.008
0.006
0.004
0.002
0
Normal
CXCL9 mRNA CXCL10 mRNA CXCL11 mRNA
CXCR3 mRNA
LIGHT mRNA HVEM mRNA
CCR4 mRNA
HVEM mRNA
**
**
**
*
*
*
*
*
* *
*
*
*
*
Early
CTCL
Advanced
CTCL
Normal EarlyCTCL
Advanced
CTCL
Normal EarlyCTCL
Advanced
CTCLNormal
Early
CTCL
Advanced
CTCL
Normal EarlyCTCL
Advanced
CTCL Normal
Early
CTCL
Advanced
CTCL
Normal EarlyCTCL
Normal
Advanced
CTCL
Advanced
CTCL
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important for the enhancement of IFN-g-induced chemokine
expression, but not sufficient for the production of the
chemokines.
Th1 cells preferentially express CXCR3 and its ligands are
essential for the migration (Annunziato et al., 1998). In some
autoimmune skin diseases, CXCR3 is expressed on skin-
homing T cells, thus mediating skin inflammation (Wenzel
and Tu¨ting, 2008). CXCR3 is expressed on tumor cells of
early CTCL and is associated with epidermotropism of tumor
cells (Lu et al., 2001; Kallinich et al., 2003). We showed that
mRNA levels of CXCR3 ligands were elevated in lesional skin
of early CTCL (Figure 3a). As expected, CXCL9, CXCL10, and
CXCL11 mRNA expression levels significantly correlated
with one another (Figure 4d). In addition, dermal fibroblasts
are stained positive for CXCL9, CXCL10, and CXCL11 in early
CTCL (Figure 5b and c). We also showed that CXCR3 mRNA
expression was increased in lesional skin of early and
advanced CTCL, whereas CCR4 mRNA expression was
elevated in advanced CTCL skin, but not in early CTCL skin
(Figure 3b). All these findings were consistent with previous
reports (Lu et al., 2001; Kakinuma et al., 2003; Kallinich
et al., 2003; Yagi et al., 2006).
LIGHT mRNA expression was elevated in lesional skin of
advanced CTCL, but not in early CTCL skin (Figure 3c).
Indeed, many LIGHT-expressing lymphoid cells were de-
tected in the dermis of advanced CTCL skin by immunohis-
tochemistry (Figure 5a). In addition, LIGHT mRNA expression
correlated with CCR4 mRNA expression (Figure 4b). Con-
versely, HVEM mRNA expression was decreased in lesional
skin of advanced CTCL (Figure 3c), and inversely correlated
with CCR4 and LIGHT mRNA expression (Figure 4b and c).
Moreover, we showed that cultured dermal fibroblasts from
lesional skin of advanced CTCL expressed lower HVEM
mRNA than those from healthy skin (Figure 3d). It is known
that fibroblasts isolated from diseased skin maintain cellular
characteristics even after isolation and in vitro culture (Asano
et al., 2004). Actually, we previously reported that cultured
fibroblasts from CTCL lesional skin have different character-
istics from those isolated from healthy skin (Miyagaki et al.,
2010). Immunohistochemistry revealed that HVEM expres-
sion on dermal fibroblasts in CTCL skin was decreased as
disease progresses (Figure 5a and c). We do not think that
abundant LIGHT expression in advanced CTCL explains the
downregulation of HVEM expression by fibroblasts because
HVEM was downregulated at mRNA levels. Moreover,
elevation of serum LIGHT levels is reported in psoriatic
patients (Chandran et al., 2010), where HVEM expression by
fibroblasts was not downregulated (Figure 5c and data not
shown). Th1–Th2 balance likely affects HVEM expression by
fibroblasts as shown in this study (Figure 1a and b). Taken
together, expression of LIGHT and CCR4 is associated with
advanced CTCL, whereas expression of HVEM, CXCR3, and
CXCR3 ligands is associated with early CTCL.
In our study, HVEM expression significantly correlated
with CXCL9 and CXCL10 expressions (Figures 4a and 5a–c).
HVEM may be related to Th1 chemokine expression in vivo
as shown with dermal fibroblasts in vitro. In advanced CTCL,
expression of CXCR3 ligands in dermal fibroblasts was
decreased (Figures 3a and 5a, b). Downregulation of HVEM
expression on the surface of dermal fibroblasts may
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Figure 4. Correlations among chemokine, chemokine receptor, LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with herpes
simplex virus glycoprotein D for herpesvirus entry mediator (HVEM), a receptor expressed by T lymphocytes), and HVEM expression levels in lesional skin of
cutaneous T cell lymphoma (CTCL). (a) Correlations between HVEM expression and CXC chemokine ligand (CXCL)9 or CXCL10 expression. (b) Inverse
correlation between HVEM expression and CC chemokine receptor (CCR)4 expression and correlation between LIGHT expression and CCR4 expression.
(c) Inverse correlation between LIGHT expression and HVEM expression. (d) Correlations among CXCL9 expression, CXCL10 expression, and CXCL11 expression.
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contribute to decrease in CXCL9, CXCL10, and CXCL11
production, resulting in a Th2-dominant microenvironment.
We also showed that tumor cells in peripheral blood of SS
expressed low levels of HVEM compared with reactive
benign T cells (Figure 5e and f). It has been shown that
LIGHT triggers apoptosis of various tumor cells, including
B cell chronic leukemia cells (Zhai et al., 1998; Yu et al.
1999; Pasero et al., 2009). Low HVEM expression on the cell
surface may allow tumor cells to escape from apoptosis in SS
patients.
In some cases with early stages of CTCL, lesional T cell
infiltrates and peripheral blood T cells exhibit a Th1 cytokine
pattern (Vowels et al., 1994; Asadullah et al., 1996a, b;
Papadavid et al., 2003). By contrast, peripheral blood T cells
and lesional skin T cells in advanced CTCL show a Th2
cytokine and chemokine pattern, expressing IL-4, CCL11,
CCL17, and CCL26 (Sugaya, 2010). A Th2-dominant
environment promotes tumor survival and progression. The
results of this study propose the following model (Supple-
mentary Figure S1 online): In early CTCL, fibroblasts express
high levels of HVEM. When Th1 cells expressing IFN-g and
LIGHT infiltrate into skin, CXCL9, CXCL10, and CXCL11 are
produced by fibroblasts, as well as by keratinocytes and
Langerhans cells (Tensen et al., 1998; Fujita et al., 2005). In
advanced CTCL, fibroblasts express less HVEM and high
numbers of Th2 cells express LIGHT, but not IFN-g.
Expression of CXCL9, CXCL10, and CXCL11 is downregu-
lated, whereas CCL17 expression by Langerhans cells and
fibroblasts is upregulated.
In conclusion, this study has revealed that low HVEM
expression on dermal fibroblasts in lesional skin of advanced
CTCL attenuates expression of Th1 chemokines, which may
contribute to a shift to a Th2-dominant microenvironment as
disease progresses. Enhancing HVEM expression or signaling
may provide another therapeutic strategy for advanced CTCL,
by shifting immune responses from Th2 to Th1.
MATERIALS AND METHODS
Tissue samples
In all, 22 patients with CTCL (17 mycosis fungoides cases, patch: 6,
plaque: 3, tumor: 7, and erythroderma: 1, and five SS cases; mean±
standard deviation age: 57.1±13.1 years, 14 males and 8 females)
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Figure 5. Immunohistochemistry of chemokines, herpesvirus entry mediator (HVEM), LIGHT (lymphotoxin-like, exhibits inducible expression, and
competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes), and phosphorylated IjBa (pIjBa) in cutaneous
T cell lymphoma (CTCL) skin and HVEM expression on circulating tumor cells in Se´zary syndrome (SS). (a) Staining of normal skin (left; n¼ 5), early
CTCL (middle; n¼ 5), and advanced CTCL (right; n¼ 10) for HVEM, LIGHT, CXC chemokine ligand (CXCL)9, CXCL10, CXCL11, and pIkBa. Arrow
indicates dermal fibroblasts. Representative pictures are shown. Bar¼ 100mm. (b–d) Cell numbers per high power field (400). Negative cells (), slightly
positive cells (þ ), and strongly positive cells (þ þ ) were counted for (b) CXCL9, CXCL10, CXCL11, (c) HVEM, and (d) pIkBa. (e) A representative flow-
cytometry histogram of HVEM using peripheral blood mononuclear cells from patients with SS. The tumor cells express Vb13.1. (f) Frequencies of
HVEM-positive cells in the malignant T cell clone and the benign T cells in peripheral blood of three patients with SS.
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and 5 healthy control subjects (50.4±11.7 years, three males and
two females) were enrolled in this study. Messenger RNA was
obtained from biopsy materials of lesional skin of patients with CTCL
and normal skin by using illustra QuickPrep Micro mRNA
Purification Kit (GE Healthcare, Buckinghamshire, UK). The medical
ethical committee of the University of Tokyo approved all described
studies and the study was conducted according to the Declaration of
Helsinki Principles. Informed consent was obtained to use skin
samples from patients and healthy controls. All patients with CTCL
were given diagnoses according to World Health Orgnization-
European Organization for Research and Treatment of Cancer
classification for cutaneous lymphomas (Willemze et al., 2005).
Patients were classified into early stages (patch and plaque; nine
cases) and advanced stages (tumor and erythroderma; 13 cases)
according to their types of skin lesions. The five healthy controls had
no history of allergy, psoriasis, or CTCL.
Cell culture
Human adult dermal fibroblasts were grown from explants of
lesional skin biopsies from five patients with advanced CTCL.
Control fibroblasts were obtained from five healthy donors at the
occasions of minor surgery. The cells were cultured in 75 cm2 cell
culture flasks (Corning, Corning, NY) at 37 1C, 5% CO2 in MEM
(Sigma, St. Louis, MO) containing 10% fetal bovine serum, penicillin
G sodium, streptomycin sulfate and amphotericin B. Third- to fifth-
passage cells were used in all experiments.
Stimulation of cells
When confluence of 75 cm2 cell culture flask was achieved, human
adult dermal fibroblasts were trypsinized, washed, and resuspended
in MEM with 10% fetal bovine serum at 1 106 cells per ml, and
1ml of cells were added to each well of the six-well plates (Becton
Dickinson, Franklin Lakes, NJ). When the cells reached semicon-
fluence, they were stimulated with recombinant IFN-g (10 ngml1;
R&D Systems, Minneapolis, MN), LIGHT (1, 10, and 100 ngml1;
Peprotech, Rocky Hill, NJ), or their combination with or without pre-
incubation with sc-514 (20 and 50 mM; Calbiochem, Darmstadt,
Germany). After 30minutes, cells were harvested for western
blotting. After 16 or 24 hours, the culture supernatants and cells
were collected. Total RNA from cells was prepared by using TRIZOL
Reagent (Invitrogen, Carlsbad, CA).
Enzyme-linked immunosorbent assay
Immunoreactive CXCL9, CXCL10, and CXCL11 in the supernatants
were quantified by human CXCL9/MIG ELISA kit, human CXCL10/
IP-10 ELISA kit, and human CXCL11/I-TAC ELISA kit (R&D Systems).
These assays employ the quantitative sandwich enzyme immuno-
assay technique. Optical densities were measured at 450 nm using a
Bio-Rad Model 550 microplate reader (Bio-Rad Laboratories,
Hercules, CA).
Quantitative real-time reverse transcriptase–PCR
cDNA was synthesized using TaqMan Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA,).Quantitative reverse transcrip-
tase (RT)–PCR was performed as described previously (Sugaya et al.,
2006). Primers for human CXCL9, CXCL10, CXCL11, CXCR3, CCR4,
LIGHT, HVEM, LTbR, and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) were described in Supplementary Table S1 online.
Western blotting
Cells were lysed in radioimmunoprecipitation buffer (Sigma)
supplemented with 1mM sodium orthovanadate, 1mM phenyl-
methylsulfonyl fluoride, and 1mM sodium fluoride. Samples were
dissolved in Electrophoresis Sample Buffer (Santa Cruz, Santa Cruz,
CA). SDS-PAGE was performed with Novex 10% Tris-Glycine Gel
(Invitrogen) and Novex Tris Gly SDS Running Buffer (Invitrogen).
After transfer to nitrocellulose membrane (Invitrogen), the membrane
was blotted with mouse anti-human phospho-IkBa mAb (Cell
Signaling Technology, Boston, MA), mouse anti-human IkBa mAb
(Cell Signaling Technology), or mouse anti-human GAPDH mAb
overnight at 4 1C and with the appropriate secondary antibody for
1 hour at room temperature. Visualization was performed by
SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rock-
ford, IL).
Immunohistochemistry
We performed immunohistochemical staining for HVEM, LIGHT,
CXCL9, CXCL10, CXCL11, and pIkBa with lesional skin of patients
with CTCL (n¼ 15, patch: 3, plaque: 2, tumor: 6, and erythroderma:
4) and with normal skin (n¼ 5). Immunohistochemical staining for
HVEM was also carried out with lesional skin of atopic dermatitis
(n¼ 5) and psoriasis (n¼ 5). Briefly, 5-mm-thick tissue sections from
formaldehyde-fixed and paraffin-embedded samples were dewaxed
and rehydrated. These sections were then stained with mouse anti-
human HVEM mAb, goat anti-human LIGHT polyclonal antibodies
(Santa Cruz), mouse anti-human CXCL9mAb, mouse anti-human
CXCL10mAb, mouse anti-human CXCL11mAb (R&D Systems),
mouse anti-human phospho-IkBa mAb, or isotype-matched IgG,
followed by ABC staining (Vector Lab, Burlingame, CA). Diamino-
benzidine was used for visualizing the staining, and counterstaining
with Mayer hematoxylin was performed, according to the manu-
facturer’s instructions. The numbers of positive cells per high power
field ( 400) were counted independently by two investigators in a
blinded manner.
HVEM expression on the cell surface
Fibroblasts were stimulated with recombinant IFN-g or IL-4 (1, 10,
and 100ngml1; R&D Systems) for 24 hours. Peripheral blood
mononuclear cells were obtained from three patients with SS by
density centrifugation over Ficoll-Paque (GE Healthcare) and
resuspended in RPMI1640 supplemented with 10% fetal bovine
serum. T cell receptor Vb expression was determined by staining
with FITC-conjugated Vb-specific mAb (Beckman Coulter, Brea,
CA). Fibroblasts and peripheral blood mononuclear cells were
stained with phycoerythrin-conjugated anti-human HVEM mAb
(BioLegend, San Diego, CA) or phycoerythrin-conjugated isotype-
matched IgG and analyzed using a FACScan flow cytometer (Becton
Dickinson).
Statistical analysis
Statistical analysis between two groups was performed using the
Mann–Whitney’s U-test. Correlation coefficients were determined by
using the Spearman’s rank correlation test. P-values o0.05 were
considered statistically significant.
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